SCHEMBL5264072

SCHEMBL5264072

CCOC(=O)c1cnc(-c2ccccc2)nc1Nc1ccnc(F)n1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.57
SMN1; SMN2 Q16637 4/20 0.57
MAPT P10636 3/20 0.57
LMNA P02545 3/20 0.57
MAPK1 P28482 2/20 0.57
ATM Q13315 1/20 0.57
NPC1 O15118 1/20 0.56
TP53 P04637 1/20 0.56
RAB9A P51151 1/20 0.56
FOS P01100 7/20 0.55
JUN P05412 7/20 0.55
NFKB1 P19838 7/20 0.55
NFKB2 Q00653 7/20 0.55
RELA Q04206 7/20 0.55
CYP1A2 P05177 4/20 0.53
POLB P06746 2/20 0.53
CYP2C9 P11712 2/20 0.53
CYP2C19 P33261 2/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
GAA P10253 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5264668 0.83 PDE4B (0.56) ALDH1A1MAPTLMNACYP1A2CYP2C9
SCHEMBL11160276 0.82 ALDH1A1 (0.67) ALDH1A1SMN1; SMN2MAPTLMNAMAPK1
SCHEMBL5914410 0.80 ALDH1A1 (0.70) ALDH1A1SMN1; SMN2MAPTLMNAMAPK1
SCHEMBL5264243 0.80 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2MAPTLMNAMAPK1
SCHEMBL11289243 0.80 ALDH1A1 (0.63) ALDH1A1SMN1; SMN2MAPTLMNAMAPK1
SCHEMBL8398530 0.79 ALDH1A1 (0.71) ALDH1A1SMN1; SMN2MAPTLMNAMAPK1
SCHEMBL11158474 0.79 ALDH1A1 (0.69) ALDH1A1SMN1; SMN2MAPTLMNAMAPK1
SCHEMBL11276702 0.79 ALDH1A1 (0.62) ALDH1A1SMN1; SMN2MAPTLMNAMAPK1
SCHEMBL11285512 0.78 ALDH1A1 (0.66) ALDH1A1SMN1; SMN2MAPTLMNAMAPK1
SCHEMBL7210767 0.77 ALDH1A1 (0.66) ALDH1A1SMN1; SMN2MAPTLMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1794135-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE Amgen Inc. (US) 2007-06-13 EP disclosed
WO-2006037117-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2006-04-06 WO disclosed
US-20060069110-A1 Substituted heterocyclic compounds and methods of use AMGEN INC. 2006-03-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060069110-A1 Substituted heterocyclic compounds and methods of use MAPT, MYLK2, IAPP ALDH1A1 3019/4885SMN1; SMN2 11/4885MAPT 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.